A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 5, 2015, Pages 881-889

  Simon, J C ^a   Dominicus, R ^b   Karl, L ^c   Rodriguez R ^d   Willers, C ^d   Dirschka, T ^e  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Hautarztzentrum Dülmen   (Germany)

^c Private practice   (Germany)

^d SA ^*  (Spain)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; FLUOROURACIL; SALICYLIC ACID; DRUG COMBINATION; IMMUNOSUPPRESSIVE AGENT; KERATOLYTIC AGENT;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE SCABBING; APPLICATION SITE VESICLE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOSURGERY; CRYOTHERAPY; DISEASE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FACE; FEMALE; FOLLOW UP; FOREHEAD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOTIC ACTINIC KERATOSIS; HYPERPIGMENTATION; HYPOPIGMENTATION; LOCAL SKIN REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SCALP; SKIN BURNING SENSATION; SKIN MACERATION; SKIN MANIFESTATION; TOPICAL TREATMENT; TREATMENT DURATION; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DRUG COMBINATION; FACIAL DERMATOSES; KERATOSIS, ACTINIC; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; CRYOSURGERY; DRUG COMBINATIONS; FACIAL DERMATOSES; FEMALE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOLYTIC AGENTS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SALICYLIC ACID; SCALP; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928311855     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12702     Document Type: Article

References (36)

1. Sterry W, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses-Update 2011. URL http://www.euroderm.org/. (last accessed: 29 August 2014).
2. National Institute for Clinical Excellence. Guidance on Cancer Services: Improving outcomes for people with skin tumours including melanoma. The manual. February 2006. URL: http://www.nice.org.uk/guidance/csgstim/resources/improving-outcomes-for-people-with-skin-tumours-including-melanoma-the-manual-2006-guidance2 (last accessed: 29 August 2014).
3. Memon AA, Tomenson JA, Bothwell J, Friedmann PS,. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-1159.
4. Frost C, Williams G, Green A,. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-277.
5. Cohen JL,. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol 2010; 3: 39-44.
6. Venna SS, Lee D, Stadecker MJ, Rogers GS,. Clinical recognition of actinic keratoses in a high-risk population: how good are we? Arch Dermatol 2005; 141: 507-509.
7. de Berker D, McGregor JM, Hughes BR,; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222-230.
8. Krawtchenko N, Roewert-Huber J, Ulrich M, et al.,. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 (Suppl 2): 34-40.
9. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G,. Management of field change in actinic keratosis. Br J Dermatol 2007; 157 (Suppl 2): 21-24.
10. Stockfleth E, Ferrandiz C, Grob JJ, et al.,. European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-659.
11. Akarsu S, Aktan S, Atahan A, et al.,. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. Clin Exp Dermatol 2011; 36: 479-484.
12. Szeimies RM, Gerritsen MJ, Gupta G, et al.,. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-555.
13. Martin G, Swanson N,. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol 2013; 68 (Suppl 1): S39-S48.
14. Szeimies RM, Karrer S, Radakovic-Fijan S, et al.,. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
15. Freeman M, Vinciullo C, Francis D, et al.,. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99-106.
16. Morton C, Campbell S, Gupta G, et al.,. AKtion Investigators. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029-1036.
17. Stockfleth E, Kerl H, Zwingers T, Willers C,. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101-1108.
18. Stockfleth E, Zwingers T, Willers C,. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol 2012; 22: 370-374.
19. Stockfleth E,. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol 2012; 11: 1462-1467.
20. Olsen EA, Abernethy ML, Kulp-Shorten C, et al.,. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratosis on the head and neck. J Am Acad Dermatol 1991; 24: 738-743.
21. Röwert-Huber J, Patel MJ, Forschner T, et al.,. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl. 3): 8-12.
22. Frost CA, Green AC,. Epidemiology of solar keratosis. Br J Dermatol 1994; 131: 455-464.
23. MacKie RM,. Textbook of Dermatology, 6th edn. Blackwell Science Ltd, Oxford, 1998: 1671.
24. Yantsos VA, Conrad N, Zabawski E, Cockerell C,. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratosis. Semin Cutan Med Surg 1999; 18: 3-14.
25. Stockfleth E, Meyer T, Benninghoff B, et al.,. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-1502.
26. Szeimies RM, Stockfleth E, Popp G, et al.,. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-414.
27. Stockfleth E, Kerl H,; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
28. Berlin JM, Rigel DS,. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol 2008; 7: 669-673.
29. Dinehart SM,. The treatment of actinic keratosis. J Am Acad Dermatol 2000; 42: 25-28.
30. Halpern AC, Hanson IJ,. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004; 43: 638-642.
31. Balkrishnan R, Cayce KA, Kulkarni AS, et al.,. Predictors of treatment choices and associated outcomes in actinic keratosis: results from a national physician survey study. J Dermatolog Treat 2006; 17: 162-166.
32. McIntyre WJ, Downs MR, Bedwell SA,. Treatment options for actinic keratoses. Am Fam Physician 2007; 76: 667-671.
33. Thai KE, Fergin P, Freeman M, et al.,. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43: 687-692.
34. Robinson J, Hanke CW, Sengelmann RD, et al.,. Surgery of the Skin. Elsevier Inc., Amsterdam, 2005: 191-197.
35. Goldberg LH, Kaplan B, Vergilis-Kalner I, Landau J,. Liquid nitrogen: temperature control in the treatment of actinic keratosis. Dermatol Surg 2010; 36: 1956-1961.
36. Poziomczyk CS, Köche B, Dornelles Mde A, Dornelles SI,. Pain evaluation in the cryosurgery of actinic keratoses. An Bras Dermatol 2011; 86: 645-650.